Abstract 1559P
Background
Prognosis for aESCC (advanced esophageal squamous cell carcinoma) remains poor. Programmed death-ligand 1 (PD-L1) expression is a well-established positive predictive biomarker for response to immunotherapy in aESCC. However, the association between PD-L1 and response to chemotherapy alone remains unclear. This study aims to determine the prognostic significance of PD-L1 expression in patients treated with first-line chemotherapy alone in aESCC.
Methods
First-line phase III randomized trials that included PD-L1 expression as a biomarker in aESCC were extracted after a systematic search of Embase and PubMed from inception until September 24, 2022. Only trials that reported PD-L1 stratified Kaplan-Meier (KM) curves of chemotherapy arms were included. A graphical reconstructive algorithm was used to estimate time-to-event outcomes from reported KM plots in all overall and reported subgroup cohorts. Where unavailable, KMSubtraction was utilized to derive KM plots of unreported PD-L1 subgroups. Thereafter, individual patient data meta-analysis was conducted. Survival analyses for overall and progression-free survival (OS, PFS) were conducted with Cox proportional hazards models with a shared-frailty term incorporated to account for inter-study differences.
Results
Chemotherapy arms from 5 randomized phase III trials - CheckMate-648, ESCORT-first, KEYNOTE-590, RATIONALE306 and ORIENT-15 – comprising 1,517 patients were included in the OS analysis. Compared to PD-L1 low expressing tumors, patients with PD-L1 high expressing tumors were at a significantly higher risk of mortality (PD-L1 high [n=769] vs PD-L1 low [n=748], HR=1.152, 95%-CI: 1.018 – 1.305, p=0.025). Three trials – CheckMate-648, ESCORT-first and ORIENT-15 – comprising 949 patients treated with chemotherapy alone were included in the PFS analysis. Likewise, patients with PD-L1 high expressing tumors were at a higher risk of tumor progression, although this was not significant (PD-L1-high [n=513] vs PD-L1-low [n=436], HR=1.076, 95%-CI: 0.923 - 1.253, p=0.35).
Conclusions
Our study found PD-L1 expression is a negative predictor of overall survival in aESCC treated with first-line chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R. Sundar: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, MSD, GSK, DKSH, Astellas; Financial Interests, Personal, Invited Speaker: MSD, Eli Lilly, BMS, Roche, Taiho, AstraZeneca, DKSH, Ipsen; Financial Interests, Personal and Institutional, Local PI: MSD, Taiho, BMS, Novartis; Financial Interests, Personal, Stocks/Shares: Teladoc; Financial Interests, Institutional, Advisory Board: Paxman Coolers; Non-Financial Interests, Advisory Role: Paxman Coolers; Non-Financial Interests, Principal Investigator: MSD, Natera. All other authors have declared no conflicts of interest.
Resources from the same session
1498P - HGF/MET pathway is associated with poor efficacy of Immune checkpoint inhibitors (ICIs) in advanced-stage NSCLC
Presenter: Assya Akli
Session: Poster session 21
1499P - Wnt5-ROR2 signalling mediated resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Etienne Giroux-Leprieur
Session: Poster session 21
1500TiP - REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design
Presenter: Ehsan Ghorani
Session: Poster session 21
1502TiP - A phase I/IIa trial of ChAdOx1 and MVA vaccines against MAGE-A3 and NY-ESO-1
Presenter: Fiona Blackhall
Session: Poster session 21
1503TiP - A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%
Presenter: Mark Awad
Session: Poster session 21
1504TiP - HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment
Presenter: WenFeng Fang
Session: Poster session 21
1505TiP - TROPION-Lung07: A phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression
Presenter: Isamu Okamoto
Session: Poster session 21
1506TiP - A single-arm, phase II study of amivantamab (AMI), lazertinib (L) and pemetrexed (P) for first-line treatment of recurrent/metastatic non-small cell lung cancers (NSCLCS) with epidermal growth factor receptor mutations in Exons 19 or 21 (EGFR 19/21): AMIGO 1 (LACOG0821)
Presenter: William Nassib William Junior
Session: Poster session 21
1507TiP - Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
Presenter: David Planchard
Session: Poster session 21